On February 18, the New Jersey Supreme Court issued opinions in two cases that had the potential to dramatically re-shape the state’s insurance law. The court resolved both cases on limited grounds that upheld pre-existing expectations while clarifying the law prospectively, as NJCJI urged it to do in an amicus brief. The court also directed the Civil Practice Committee to take up broader policy questions for further study.
A selection of the need-to-know civil justice news for the [...]
For over a century, Americans have relied on the federal Food and Drug Administration (FDA) to regulate the quality and safety of everything from pharmaceutical products and medical devices to the labels on prepared foods. However, there is a growing trend in the courts that would allow lawsuits over these FDA approved items and their labels, effectively subjecting them to ad hoc regulation at the state level via litigation. On February 10, 2015, the New Jersey Civil Justice Institute hosted a panel discussion on this constantly evolving and critically important area of law with former Solicitor General Paul Clement of Bancroft PLLC; Gerald Masoudi of Covington & Burling LLP, who is the former Chief Counsel of the FDA; and Andrew Boczkowski, an Assistant General Counsel at GlaxoSmithKline.
The New Jersey Consumer Fraud Act has been the focus of several news stories this week since a state court judge issued a ruling that will allow a CFA-based lawsuit over “gay conversion therapy” to move forward.
A selection of the need-to-know civil justice news for the [...]
Each quarter, the Judiciary Times publishes statewide and local news [...]
Although A4097, which would place additional restrictions on contract into the state’s Truth-in-Consumer Contract, Warranty and Notice Act (TCCWNA), is not on its face an anti-arbitration bill, that is its effect. That much was made clear when the Assembly Consumer Affairs Committee held a hearing on the bill on February 5.
On February 5th, the Assembly Health and Senior Services Committee [...]
A lot of ink has been spilled over the federal corruption charges that have been filed against longtime New York Assembly Speaker Sheldon Silver. At the heart of the case is the sharing of asbestos patients/clients by doctors and law firms tied to Silver on an apparent quid pro quo basis.
This Thursday, the New Jersey Civil Justice Institute will be testifying in opposition to two important bills coming up for hearings in their respective committees - A4041, which allows for the retroactive application of New Jersey’s False Claims Act in some circumstances, and A4097, which places additional restrictions on contract into the state’s Truth-in-Consumer Contract, Warranty and Notice Act (TCCWNA). Both bills would incentivize litigation and worsen New Jersey’s business climate.
